Journal article · 2016 · Open access

Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis

Myrto T. Samara, Markus Dold, Myrsini Gianatsi, Adriani Nikolakopoulou, Bartosz Helfer, Georgia Salanti, Stefan Leucht

JAMA Psychiatry, 73(3), 199 · Published 4 February 2016 · DOI 10.1001/jamapsychiatry.2015.2955

Open PDFView at the publisherCite this paper

In brief

“Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis” is a 2016 journal article by Myrto T. Samara and 6 co-authors, published in JAMA Psychiatry. OpenAlex counts 350 citations as of 20 November 2026, which puts it in the top 1% of works published in 2016 by citations. It is open access: the full text is free to read at JAMA Psychiatry.

Citations
350
Most cited in
2020 (41)
Field-weighted impact
26.97
References
116
Authors
7

Abstract

IMPORTANCE: In treatment-resistant schizophrenia, clozapine is considered the standard treatment. However, clozapine use has restrictions owing to its many adverse effects. Moreover, an increasing number of randomized clinical trials (RCTs) of other antipsychotics have been published. OBJECTIVE: To integrate all the randomized evidence from the available antipsychotics used for treatment-resistant schizophrenia by performing a network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Biosis, PsycINFO, PubMed, Cochrane Central Register of Controlled Trials, World Health Organization International Trial Registry, and clinicaltrials.gov were searched up to June 30, 2014. STUDY SELECTION: At least 2 independent reviewers selected published and unpublished single- and double-blind RCTs in treatment-resistant schizophrenia (any study-defined criterion) that compared any antipsychotic (at any dose and in any form of administration) with another antipsychotic or placebo. DATA EXTRACTION AND SYNTHESIS: At least 2 independent reviewers extracted all data into standard forms and assessed the quality of all included trials with the Cochrane Collaboration's risk-of-bias tool. Data were pooled using a random-effects model in a Bayesian setting. MAIN OUTCOMES AND MEASURES: The primary outcome was efficacy as measured by overall change in symptoms of schizophrenia. Secondary outcomes included change in positive and negative symptoms of schizophrenia, categorical response to treatment, dropouts for any reason and for inefficacy of treatment, and important adverse events. RESULTS: Forty blinded RCTs with 5172 unique participants (71.5% men; mean [SD] age, 38.8 [3.7] years) were included in the analysis. Few significant differences were found in all outcomes. In the primary outcome (reported as standardized mean difference; 95% credible interval), olanzapine was more effective than quetiapine (-0.29; -0.56 to -0.02), haloperidol (-0. 29; -0.44 to -0.13), and sertindole (-0.46; -0.80 to -0.06); clozapine was more effective than haloperidol (-0.22; -0.38 to -0.07) and sertindole (-0.40; -0.74 to -0.04); and risperidone was more effective than sertindole (-0.32; -0.63 to -0.01). A pattern of superiority for olanzapine, clozapine, and risperidone was seen in other efficacy outcomes, but results were not consistent and effect sizes were usually small. In addition, relatively few RCTs were available for antipsychotics other than clozapine, haloperidol, olanzapine, and risperidone. The most surprising finding was that clozapine was not significantly better than most other drugs. CONCLUSIONS AND RELEVANCE: Insufficient evidence exists on which antipsychotic is more efficacious for patients with treatment-resistant schizophrenia, and blinded RCTs-in contrast to unblinded, randomized effectiveness studies-provide little evidence of the superiority of clozapine compared with other second-generation antipsychotics. Future clozapine studies with high doses and patients with extremely treatment-refractory schizophrenia might be most promising to change the current evidence.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016). Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry, 73(3), 199. https://doi.org/10.1001/jamapsychiatry.2015.2955

MLA 9

Samara, Myrto T., et al. “Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.” JAMA Psychiatry, vol. 73, no. 3, 2016, p. 199. https://doi.org/10.1001/jamapsychiatry.2015.2955.

Chicago

Samara, Myrto T., Markus Dold, Myrsini Gianatsi, Adriani Nikolakopoulou, Bartosz Helfer, Georgia Salanti, and Stefan Leucht. 2016. “Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.” JAMA Psychiatry 73 (3): 199. https://doi.org/10.1001/jamapsychiatry.2015.2955.

Harvard

Samara, M. T. et al. (2016) ‘Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis’, JAMA Psychiatry, 73(3), p. 199. doi:10.1001/jamapsychiatry.2015.2955.

IEEE

M. T. Samara et al., “Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis,” JAMA Psychiatry, vol. 73, no. 3, p. 199, 2016, doi: 10.1001/jamapsychiatry.2015.2955.

BibTeX

@article{samara2016efficacy,
  title     = {{Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis}},
  author    = {Samara, Myrto T. and Dold, Markus and Gianatsi, Myrsini and Nikolakopoulou, Adriani and Helfer, Bartosz and Salanti, Georgia and Leucht, Stefan},
  journal   = {JAMA Psychiatry},
  year      = {2016},
  volume    = {73},
  number    = {3},
  pages     = {199},
  doi       = {10.1001/jamapsychiatry.2015.2955},
  url       = {https://doi.org/10.1001/jamapsychiatry.2015.2955}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20173939
20183434
20194040
20204141
20213232
20223333
20232525
20243939
20252525
20261717

Its field-weighted citation impact is 26.97: it has been cited 26.97 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • treatment-resistant schizophrenia
  • antipsychotic drugs
  • clozapine
  • olanzapine
  • quetiapine
  • haloperidol
  • sertindole
  • risperidone

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016). Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry, 73(3), 199. https://doi.org/10.1001/jamapsychiatry.2015.2955

How many times has this paper been cited?

350 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at JAMA Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

Myrto T. Samara, Markus Dold, Myrsini Gianatsi, Adriani Nikolakopoulou, Bartosz Helfer, Georgia Salanti, Stefan Leucht.

What is the DOI of this paper?

10.1001/jamapsychiatry.2015.2955, permanently at https://doi.org/10.1001/jamapsychiatry.2015.2955. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.